linjc16/ctgov huggingface dataset:
Recurrent Extrahepatic Bile Duct Stones as a Late Complication of ERCP in Patients With Coexisting Intra- and Extrahepatic Bile Duct Stones

Study Overview
=================
Brief Summary
-----------------
The management of coexisting intrahepatic bile duct (IBD) and extrahepatic bile duct (EBD) stones is complicated and requires a multidisciplinary approach. The long-term clinical outcomes of patients initially treated with endoscopic retrograde cholangiopancreatography (ERCP) EBD stone extraction remain unclear. Investigators conducted a retrospective study of patients with coexisting IBD and EBD to investigate the long-term impact of ERCP on the incidence of recurrent EBD stones and to identify risk factors of recurrence.

Official Title
-----------------
Recurrent Extrahepatic Bile Duct Stones as a Late Complication of ERCP in Patients With Coexisting Intra- and Extrahepatic Bile Duct Stones：a Long-term Retrospective Cohort Study

Conditions
-----------------
Intrahepatic Bile Duct Stone, Choledocholithiasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-gastrointestinal tract reconstruction patients with coexisting IBD and EBD stones who underwent ERCP between July 2008 and December 2020 at Xijing Hospital in China Exclusion Criteria: patients with benign or malignant EBD strictures sclerosing cholangitis suspected choledochal cysts liver cirrhosis parasitic liver diseases long-term biliary drainage with biliary stents or percutaneous tubes without a definitive IBD stone or with a diagnosis of liver calcification as determined by imaging review medical records or follow-up information was unavailable
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the recurrence rate of EBD stones | Stone recurrence was defined as new EBD stone formation beyond 3 months after complete initial clearance. | up to 2 years |
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.

Official Title
-----------------
A 12-month, Randomized, Single-blind, Placebo-controlled Exposure-response Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)

Conditions
-----------------
Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Biological: TCD601
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to understand the study requirements and provide written informed consent before any study assessment is performed Male or female patients ≥ 18 to 45 years of age A diagnosis of type 1 diabetes Exclusion Criteria: Women who are pregnant, lactating, or planning on pregnancy during the study History of cancer History of heart disease Recent infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TCD601<br>Administered one of three doses of TCD601 over a 12 week treatment period. | Biological: TCD601<br>* Investigational Product<br>|
| Placebo Comparator: Placebo<br>Placebo is administered over a 12 week treatment period. | Other: Placebo<br>* Comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in beta-cell function as compared to placebo at week 52. | Assess any changes in beta-cell function at the end of the study (week 52) for patients treated with TCD601 (study drug) compared to subjects treated with placebo (the comparator). | 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the incidence and severity of adverse | Number of adverse events compared to placebo at week 52. | 52 weeks |
Endovascular Treatment for AIS in Chinese Municipal and County Hospitals： A Real World Study-ETERNITY Registry

Study Overview
=================
Brief Summary
-----------------
To investigate the Endovascular Treatment difference between Chinese city and country hospital.

Detailed Description
-----------------
Endovascular Treatment for AIS in Chinese Municipal and County Hospitals： A Real World Study-ETERNITY Registry is an academic , independent, pragmatic , prospective , multicenter , observational registry study . Patients with acute ischemic stroke caused by anterior circulation intracranial large vessel occlusion and receiving EVT were included. Patients were divided into primary stroke center (county hospital) and senior stroke center (city hospital) groups. Acute ischemic stroke (AIS) workflow, EVT procedural details and clinical outcome were compared in two groups. The aim of the study was to explore the EVT difference in Chinese city and county hospital.

Official Title
-----------------
Endovascular Treatment for Acute Ischemic Stroke in Chinese Municipal and County Hospitals： A Real World Study-ETERNITY Registry

Conditions
-----------------
Endovascular Treatment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) age ≥18 years; (2) diagnosis of AIS caused by imaging-confirmed intracranial LVO, including isolated cervical internal carotid artery or tandem occlusion, intracranial internal carotid artery, middle cerebral artery (M1/M2), anterior cerebral artery (A1/A2); (3) initiation of any type of EVT, including mechanical thrombectomy, emergent angioplasty via balloon or/and stent; (4).Onset-to-presentation time with 24 hours; (5).Patients whose onset-to-presentation time surpass 6 hours should had CTP and fulfill with DAWN[6] or DEFUSE's[7] criteria. Exclusion Criteria: (1) Without follow up outcome; (2) posterior circulation stroke;(3)no evidence of LVO on angiogram.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The modified Rankin Scale score at 90 days | The range of the modified Rankin Scale is from 0 to 6. A higher score indicates a worse outcome. 0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead. | 90 days | 
| Baseline CT/magnetic resonance and CT angiography/magnetic resonance angiography imaging, digital subtraction angiography | Radiological assessment included ASPECTS ，location of occlusion site, presence of underlying ICAS ，or exist microcatheter First-Pass Effect. | 90 days | 
| Successful reperfusion | Successful reperfusion was defined as eTICI ≥2b | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endovascular Treatment, acute ischemic stroke
Assessment of Schizophrenia Patients' Clinical Study Experiences

Study Overview
=================
Brief Summary
-----------------
The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all schizophrenia patients as well as those in under-represented demographic groups.

Official Title
-----------------
Insights From Participants: Candid Accounts of Schizophrenia Clinical Trials Patients

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of schizophrenia Considered reliable, able to understand, and willing to perform all study procedures Signed Written Informed Consent Exclusion Criteria: Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study Any serious and/or unstable pre-existing medical disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of schizophrenia patients who decide to enroll in a clinical trial |  | 3 months | 
| Rate of schizophrenia patients who remain in clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia
Effectiveness of Neck Isometric Exercises and Cervical Mobilization on Cervical Radiculopathy

Study Overview
=================
Brief Summary
-----------------
Effectiveness of neck isometric exercises and cervical mobilization will be compared to observe the efficacy of these techniques on cervical radiculopathy

Detailed Description
-----------------
Two groups will be formed to observe the efficacy of neck isometric exercises and cervical mobilization on cervical radiculopathy by using NPRS, ROM and QoL tools.

Official Title
-----------------
Effectiveness of Neck Isometric Exercises and Cervical Mobilization on Cervical Radiculopathy

Conditions
-----------------
Cervical Radiculopathy

Intervention / Treatment
-----------------
* Other: Isometric exercises
* Other: Mobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females with age between 25-50 years Patients referred from neuro and orthopedic departments with diagnosed cervical radiculopathy. Complaint of neck pain on neck bending with positive spurling's test. Complaint of neck pain, numbness and tingling in arm with positive spurling's test. Exclusion Criteria: Cervical Trauma Any other orthopedic and neurological conditions of cervical spine. Fracture Malignancy

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: A single blind RCT
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental<br>neck isometric exercises will be administered at for 4 weeks and will be evaluuated at baseline, 2nd and after 4 weeks of interventions | Other: Isometric exercises<br>* These exercises are used to increase muscle endurance, power and ROM<br>|
| Active Comparator: control<br>cervical mobilization will be administered at for 4 weeks and will be evaluuated at baseline, 2nd and after 4 weeks of interventions | Other: Mobilization<br>* These exercises are used to increase ROM and used for pain reduction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numeric Pain Rating Scale | 0 means no pain and 10 means worst pain ever | 4 weeks | 
| Range of motion | Goniometer will be used to assess the ranges. lower values means more limited ROM and more values means normal | 4 weeks |
The Effects of Non Harmonic and White Noise on Human Pain Sensitivity: a Study of Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
Study the effects of 60dB and 80dB white noise, 50-70dB and 70-90dB non harmonic tones on the basic pain threshold of subjects, including the threshold and tolerance of electrical stimulation pain,the threshold and tolerance of cold pain stimulation, and the threshold and tolerance of tenderness stimulation.

Official Title
-----------------
The Effects of Non Harmonic and White Noise on Human Pain Sensitivity: a Study of Healthy Volunteers

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Behavioral: noise stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 18 and 35, regardless of gender No serious chronic diseases There is no self-reported history of chronic opioid drug use or neuropathy Exclusion Criteria: A history of alcohol or drug abuse Pregnant or lactating Severe cardiovascular, kidney, or liver diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: noise on pain<br>Comparison of pain sensitivity before and after hearing noise among 15 subjects in each group. | Behavioral: noise stimulation<br>* Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mechanical pain sensitivity | Each participant was measured using the pressure pain threshold and tolerance (tested by a pressure meter), which lower value present higher pain sensitivity | from the study beginning to 30 min after the procedure | 
| cold pain sensitivity | Each participant was measured using the cold pain threshold and tolerance (tested by immersion the hand in 4℃ water), which lower value present higher pain sensitivity | from the study beginning to 30 min after the procedure | 
| electrical pain sensitivity | Each participant was measured using the cold pain threshold and tolerance (tested by a electrical stimulator), which lower value present higher pain sensitivity | from the study beginning to 30 min after the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Noise, Pain
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Study Overview
=================
Brief Summary
-----------------
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Official Title
-----------------
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Conditions
-----------------
FAP, Lynch Syndrome, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC) Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC. Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All participants<br>Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic. | Other: Data collection<br>* Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Database creation | A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility. | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pancreas, database
Patient Perspectives in Squamous Cell Carcinoma Clinical Trials

Study Overview
=================
Brief Summary
-----------------
Clinical research participation has historically been heavily biased toward specific demographics. This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma. People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.

Official Title
-----------------
An In Depth Study Examining Patterns in the Clinical Trial Experiences of Squamous Cell Carcinoma Patients

Conditions
-----------------
Squamous Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old Confirmed diagnosis of squamous cell carcinoma Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: Inability to provide written informed consent Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study Enrolled in another research study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a squamous cell carcinoma clinical trial |  | 3 months | 
| Rate of patients who remain in squamous cell carcinoma clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
squamous cell carcinoma
The Biomechanical Study of Diseased Human Carotid, Femoral and Abdominal Aortic Tissue

Study Overview
=================
Brief Summary
-----------------
This cross-sectional study aims to ascertain the mechanical properties of human carotid/femoral atherosclerotic plaque and abdominal aortic aneurysm tissue and correlate tissue mechanics with novel blood-based biomarkers of cardiovascular calcification.

Detailed Description
-----------------
The study is a non-randomised, controlled, cross-sectional study of diseased human carotid, femoral and abdominal aortic tissue.

Official Title
-----------------
The Biomechanical Study of Diseased Human Carotid, Femoral and Abdominal Aortic Tissue

Conditions
-----------------
Vascular Diseases

Intervention / Treatment
-----------------
* Other: No intervention.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with arterial plaque undergoing treatment where the plaque tissue will be surgically removed as per the usual peripheral endarterectomy procedure. Able to provide informed consent. Exclusion Criteria: Patients that are unable to give informed consent. Seriously ill/unconscious patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention.|No intervention.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calcification feature classification | Identification of particular calcification features of plaque tissue and their influence on mechanical properties which may help clarify the success of stenting in certain patient cohorts compared to others and elucidate the procedural risk of endovascular treatments in plaque with certain calcification types. | 10 years | 
| Biomarker Analysis | Identification of novel biomarkers of vascular calcification could potentially be used as a predictive tool to highlight those at greatest risk of adverse peri-operative events, to allow for tailored medical treatment approaches and to stream-line patient care and improve patient outcomes. | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular Health Critical Mass | To build a critical mass in cardiovascular health, an area of strategic importance for healthcare in Ireland. | 10 years |